CN105358148A - 用于治疗肾小球疾病的losmapimod - Google Patents

用于治疗肾小球疾病的losmapimod Download PDF

Info

Publication number
CN105358148A
CN105358148A CN201480038296.4A CN201480038296A CN105358148A CN 105358148 A CN105358148 A CN 105358148A CN 201480038296 A CN201480038296 A CN 201480038296A CN 105358148 A CN105358148 A CN 105358148A
Authority
CN
China
Prior art keywords
glomerular
nicotinamide
fluoro
phenyl
cyclopropylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480038296.4A
Other languages
English (en)
Chinese (zh)
Inventor
D.斯普雷彻尔
R.N.维勒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CN105358148A publication Critical patent/CN105358148A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480038296.4A 2013-07-10 2014-07-08 用于治疗肾小球疾病的losmapimod Pending CN105358148A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844491P 2013-07-10 2013-07-10
US61/844491 2013-07-10
PCT/EP2014/064508 WO2015004089A1 (en) 2013-07-10 2014-07-08 Losmapimod for use in treating glomerular disease

Publications (1)

Publication Number Publication Date
CN105358148A true CN105358148A (zh) 2016-02-24

Family

ID=51134104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038296.4A Pending CN105358148A (zh) 2013-07-10 2014-07-08 用于治疗肾小球疾病的losmapimod

Country Status (9)

Country Link
US (1) US9707219B2 (enExample)
EP (1) EP3019168A1 (enExample)
JP (1) JP2016523943A (enExample)
KR (1) KR20160030206A (enExample)
CN (1) CN105358148A (enExample)
AU (1) AU2014289296A1 (enExample)
CA (1) CA2917277A1 (enExample)
RU (1) RU2015156417A (enExample)
WO (1) WO2015004089A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732910A (zh) * 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) * 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
GB201821138D0 (en) * 2018-12-21 2019-02-06 Benevolentai Bio Ltd Compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633416A (zh) * 2002-02-12 2005-06-29 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
WO2007144390A1 (en) * 2006-06-16 2007-12-21 Smithkline Beecham Corporation Use of a p38 kinase inhibitor for treating psychiatric disorders
WO2014014706A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006046528A1 (ja) * 2004-10-29 2008-05-22 興和株式会社 糸球体疾患治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633416A (zh) * 2002-02-12 2005-06-29 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
WO2007144390A1 (en) * 2006-06-16 2007-12-21 Smithkline Beecham Corporation Use of a p38 kinase inhibitor for treating psychiatric disorders
WO2014014706A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732910A (zh) * 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN114748622A (zh) * 2017-10-05 2022-07-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd

Also Published As

Publication number Publication date
KR20160030206A (ko) 2016-03-16
US20160220550A1 (en) 2016-08-04
JP2016523943A (ja) 2016-08-12
CA2917277A1 (en) 2015-01-15
AU2014289296A1 (en) 2016-02-04
RU2015156417A (ru) 2017-08-15
US9707219B2 (en) 2017-07-18
WO2015004089A1 (en) 2015-01-15
EP3019168A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
AU2012330885B2 (en) Oral immediate release formulations for substituted quinazolinones
JP7296190B2 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
JP2014507476A (ja) 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物
JP2005511722A (ja) Ｂｉｒｂ７９６ｂｓの投与方法
JP2005511722A6 (ja) Ｂｉｒｂ７９６ｂｓの投与方法
JP6940411B2 (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
JP6621534B2 (ja) 慢性咳の処置のためのオルブピタント
RS61053B1 (sr) Pоstupak za sprečavanje i / ili lečenje kognitivnog oštećenja povezanog sa starenjem i neuroinflamacijom
US20230190754A1 (en) Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
CN105358148A (zh) 用于治疗肾小球疾病的losmapimod
EP4360631A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
JP2007518768A (ja) 有機化合物の組み合わせ物
WO2023076404A1 (en) Methods for treating systemic lupus erythematosus
JPWO2006046528A1 (ja) 糸球体疾患治療剤
AU2025271047A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
JP2008127365A (ja) アレルギー性疾患の予防及び／又は治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160224